Skip to main content

Drug Interactions between cabazitaxel and ribociclib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

cabazitaxel ribociclib

Applies to: cabazitaxel and ribociclib

Coadministration with CYP450 3A4 inhibitors is not expected to have clinically significant effects on the plasma concentrations of cabazitaxel, a narrow therapeutic index drug, which is primarily metabolized via the isoenzyme. A drug interaction study in patients with advanced cancers (n=13), revealed repeated administration of the moderate CYP450 3A4 inhibitor aprepitant (125 mg or 80 mg once daily) did not modify the exposure to cabazitaxel (15 mg/m2 intravenous). Clinical data with less potent CYP450 3A4 inhibitors are not available.

References (6)
  1. (2010) "Product Information. Jevtana (cabazitaxel)." sanofi-aventis
  2. (2023) "Product Information. CABAZitaxel (Accord) (CABAZitaxel)." Accord Healthcare Pty Ltd, 2.0
  3. (2023) "Product Information. Cabazitaxel (cabazitaxel)." Dr. Reddy's Laboratories Canada Inc.
  4. (2024) "Product Information. Cabazitaxel (cabazitaxel)." Genus Pharmaceuticals Ltd
  5. (2024) "Product Information. CABAZITAXEL DR. REDDYS (cabazitaxel)." REDDY PHARMA IBERIA S.A.
  6. (2023) "Product Information. Jevtana (cabazitaxel)." sanofi-aventis

Drug and food interactions

Moderate

ribociclib food

Applies to: ribociclib

GENERALLY AVOID: Pomegranates and grapefruit may increase the systemic exposure to ribociclib. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in these fruits. Increased exposure to ribociclib may increase the risk of adverse effects such as infections, neutropenia, leukopenia, anemia, thrombocytopenia, anorexia, nausea, vomiting, diarrhea, stomatitis, alopecia, fatigue, headache, and abnormal liver function may be increased.

MANAGEMENT: Patients receiving ribociclib should avoid consumption of pomegranates or pomegranate juice and grapefruit or grapefruit juice during treatment.

References (1)
  1. (2017) "Product Information. Kisqali (ribociclib)." Novartis Pharmaceuticals

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer